A rare comet brightens the night skies in October
Mountain Dew is putting the mountain back in its logo
The money you forfeit when you cash out of your 401(k) can be staggering
Rights groups ask Filipinos to reject ex-Pres Duterte and detained preacher in upcoming elections
Israel carries out new strikes in Gaza, UN chief says many trapped in north
China stocks get a reality check; Europe shudders
Boeing withdraws contract offer after talks with striking workers break down
Trump looks to make inroads into Biden country with Scranton stop
Louisiana’s Cajun and Creole heritage will be showcased at 50th annual Festivals Acadiens et Creoles
Tatis homers again as the Padres beat the Dodgers 6-5 for a 2-1 NLDS lead
(Reuters) - The U.S. Food and Drug Administration said on Tuesday it had warned a website called ozempen.com against unlawfully selling versions of Novo Nordisk's weight-loss drugs.
Surging demand has outpaced supply for Novo's Ozempic, Eli Lilly's Mounjaro and other GLP-1 drugs that promote weight loss, fueling a growing global market for counterfeit versions.
The FDA said the website was offering unapproved versions of obesity and diabetes drugs Ozempic and Wegovy.
"These products are only available pursuant to a prescription from a licensed practitioner," the health regulator said.
Last month, the World Health Organization issued warnings on fake drugs claiming to contain the active ingredient found in Ozempic and Wegovy.
Lilly and Novo have sued several entities to stop them from selling products claiming to contain the active ingredients tirzepatide and semaglutide that are used in their respective popular diabetes and weight-loss drugs.
(Reporting by Christy Santhosh in Bengaluru; Editing by Maju Samuel)
